Table 1.
An overview of aberrant CD5 expression in B-cell malignancies.
| Malignancy | Genetic abnormalities | % | Pathogenesis | Prognosis | Ref. |
|---|---|---|---|---|---|
| B-CLL | Not mentioned | >90% | Induces IL-10 production and defect in negative regulation of BCR | CR | 6,13 |
| B-PLL | T(11;14) | One-third of Cases | NR | CR | 22 |
| MCL | Great genetic complexity in Blastoid & Pleomorphic variants | Most cases | NR | Good | 4,26-28 |
| DLBCL | Gain and loss of chromosome | 5-10% | Unfavorable Clinicopathologic features | Poor | 2,7,31,32 |
| FL | Gain in CHr. 1, 3, 5, X and loss of Chr. 2, 13, Y chromosome | Rare | Different Clinicopathologic features from classic type | Poor | 33-36,47 |
| SMZL | Del7q, Del17p13 | 20% | NR | CR | 38-43 |
| B-ALL | Trisomy 22 | Rare | NR | Poor | 45,46,48 |
B-CLL, B-chronic lymphocytic leukemia; B-PLL, B-prolymphocytic leukemia; MCL, mantle cell lymphoma; DLBCL, diffuse large b-cell lymphoma; FL, follicular lymphoma; SMZL, splenic marginal zone lymphoma; B-ALL, b-acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; BCR, B-cell receptor; Chr, chromosome; IL-10, interleukin-10; CR, controversial reported; NR, not reported.